ViCentra, a European medical technology company focused on transforming insulin delivery for people living with diabetes, has announced the close of an $85 million Series D funding round. The round was led by Innovation Industries and included matching participation from existing investors Partners in Equity and Invest-NL. Longtime supporters EQT Life Sciences and Health Innovations also returned, reinforcing their continued belief in ViCentra’s vision.
With this funding, ViCentra is entering a phase of accelerated growth. The company plans to scale up manufacturing, launch its next-generation Kaleido 2 patch pump across Europe, and begin preparations for entry into the U.S. market. These efforts mark a significant step forward in ViCentra’s mission to make insulin delivery more intuitive, personalized, and accessible for people managing diabetes.
Kaleido stands out in a crowded field of insulin delivery devices. It is currently the smallest and lightest patch pump available, designed not just for clinical performance but also for lifestyle integration. Unlike traditional medical devices, Kaleido is built to feel more like personal technology. It features premium materials and offers users the ability to choose from a range of ten aluminum shell colors, allowing for a degree of personalization rarely seen in medical equipment. This attention to design and user experience reflects ViCentra’s belief that medical devices should fit seamlessly into daily life, rather than disrupting it.
The Kaleido system is also technologically advanced. It integrates with Diabeloop’s self-learning algorithm for automated insulin delivery and is compatible with the Dexcom continuous glucose monitoring sensor. This combination enables responsive insulin management tailored to each user’s individual needs. The result is a system that not only improves clinical outcomes but also enhances quality of life by reducing the burden of diabetes management.
Initial commercial rollout in Germany, France, and the Netherlands has exceeded expectations, with demand outpacing early projections. This strong uptake has validated ViCentra’s product-market fit and created a clear path for expansion. The Series D funding will enable the company to meet growing demand, scale operations, and accelerate revenue growth as it moves into new markets.
The broader context for ViCentra’s growth is the rapidly expanding global insulin delivery market. As diabetes rates continue to rise worldwide, the need for effective, user-friendly treatment options has never been greater. The insulin pump market alone is projected to surpass $14 billion by 2034, with patch pumps emerging as the fastest-growing segment. This shift reflects a broader trend toward compact, wearable, and patient-centric solutions—an area where ViCentra is already leading.
ViCentra’s approach combines clinical rigor with thoughtful design, providing a compelling alternative to traditional systems that often prioritize function over form. By focusing on both, the company is helping redefine what diabetes care can look and feel like. Its products are not only medically effective but also emotionally resonant, giving users a sense of control and dignity in managing their condition.
KEY QUOTES:
“Kaleido is a true disruptor — small, discreet, featherlight, and beautifully designed. It empowers people with diabetes by offering a more personal and distinctive choice in both function and style. Built with empathy and precision, it honors those who live with diabetes every day. With this funding, we can now meet surging European demand and fast-track our entry into the U.S. market. This is a pivotal moment — for ViCentra, and for the community we serve.”
Tom Arnold, Chief Executive Officer at ViCentra
“ViCentra is redefining insulin pump therapy with a platform that truly centers the user experience – combining clinical performance with design simplicity and wearability. At Innovation Industries, we invest in pioneering companies that blend world-class technology with clear commercial potential. ViCentra exemplifies this by delivering a next-generation system addressing the urgent need for better treatment options in diabetes care. We’re proud to lead this investment round and partner with Tom and the team as they deepen and expand their presence in Europe and prepare for U.S. entry.”
Caaj Greebe, Partner at Innovation Industries
